KRAS and malignant colon neoplasm: miR143-3p has been shown to be downregulated in colon cancer samples; upregulation of miR143-3p by transfection of HT-29 colon cancer cell line resulted in decreased expression of ERK5 and its upstream activator, KRAS protein [15].